The FACE trial: Letrozole or anastrozole as initial adjuvant therapy?

Cancer Investigation

Volumn 25, Issue 1, 2007, Pages 14-18

  Jonat, Walter ^a   Mundhenke, Christoph ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Head to head comparison of aromatase inhibitor; Optimizing adjuvant endocrine breast cancer therapy

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; LETROZOLE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; ONCOGENE NEU; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III; FEMALE; HUMANS; LYMPHATIC METASTASIS; MULTICENTER STUDIES; NITRILES; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRIAZOLES;

EID: 33947255652     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701226990     Document Type: Article

References (16)

1. Winer, E.P.; Hudis, C.; Burstein, H.J.; Wolff, A.C.; Pritchard, K.I.; et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J. Clin. Oncol. 2005, 23, 619-629.
2. Goldhirsch, A.; Glick, J.H.; Gelber, R.D.; Coates, A.S.; Thurlimann, B.; Senn. H.J. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann. Oncol. 2005, 16, 1569-1583.
3. Thurlimann, B.; Keshaviah, A.; Coates, A.S.; Mouridsen, H.; Mauriac, L.; et al. Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 2005, 353, 2747-2757.
4. Howell, A.; Cuzick, J.; Baum, M.; Buzdar, A.; Dowsett, M.; et al. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365, 60-62.
5. Rose, C.; Vtoraya, O.; Pluzanska, A.; Davidson, N.; Gershanovich, M.; et al. An open randomized trial of second-line endocrine therapy in advanced breast cancer, comparison of the aromatase inhibitors letrozole and anastrozole. Eur. J. Cancer 2003, 39, 2318-2327.
6. Geisler, J., Haynes, B., Anker, G., Dowsett, M., Lonning, P.E. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross over study. J. Clin. Oncol. 2002, 20, 751-757.
7. Dixon, J.M.; Renshaw, L.; Young, O.; Murray, J.; Macaskill, D.J.; et al. Letrozole suppresses plasma oestradiol (E2) levels more completely than anastrozole in postmenopausal women with breast cancer. Proc. Am. Soc. Clin. Oncol. 2006, 24, 15S (Abstr. 552).
8. Dowsett, M.; Cuzick, J.; Wale, C.; Howell, T.; Houghton, J.; Baum, M. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J. Clin. Oncol. 2005, 23, 7512-7517.
9. Viale, G.; Regan, M.; Dell'Orto, P.; Del Curto, B.; Braye, S.; et al. Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Res. Treat. 2005, 94(Suppl.1), 44a.
10. Buzdar, A.U.; on behalf of the ATAC Trialists' group. Impact of adjuvant chemotherapy prior to endocrine therapy: 68 month results from the Arimidex. Tamoxifen. Alone or in Combination (ATAC) trial. J. Clin. Oncol. 2005, 23(Suppl.16), 30s (Abstr. 608).
11. Goss, P.E.; Ingle, J.N.; Martino, S.; Robert, N.J.; Muss, H.B.; et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17. J. Natl. Cancer Inst. 2005, 97, 1262-1271.
12. Mauriac, L.; Keshaviah, A.; Debled, M.; Mouridsen, H.; Forbes, J.; et al. Predictors of early recurrence in postmenopausal women with hormone receptor positive breast cancer in the BIG 1-98 trial. Eur. J. Cancer Suppl. 2006, 4(2), 111 (Abstr. 219).
13. McArthur, H.L; Olivotto, I.; Gelmon, K.A.; Speers, C.H.; Chia, S.; Ellard, S.; Kennecke. H.F. Risk of early relapse in post-menopausal women with early stage, estrogen receptor positive (ER+) breast cancer on tamoxifen. Breast Cancer Res. Treat. 2005, 94(Suppl. 1). S124 (Abstr. 3001).
14. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365, 1687-1717.
15. Mouridsen, H; Robert, N. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women. Eur. J. Cancer 2005, 41, 1678-1689.
16. De Boer, R.; Burris, H.; Monnier, A.; Mouridsen, H.; O'Shaughnessy, J.; et al. on behalf of the H211 trial steering committee. The head to head trial: letrozole vs anastrozole as adjuvant treatment of postmenopausal patients with node positive breast cancer. Proc. Soc. Clin. Oncol. 2006, 24, 582S (Abstr. 10672).